A CRA expert provided input to the Canadian Competition Bureau in its evaluation of the proposed merger of two branded pharmaceutical manufacturers. CRA’s team considered the ability and incentive of the merging parties to increase the price of a branded pharmaceutical following the merger. Aspects of this consideration included setting out the features of list and net pricing of branded drugs in the Canadian pharmaceutical marketplace, and the various constraints and factors that bear on those prices.
Antitrust implications of the build vs. buy playbook in the AI era
The rapid growth of artificial intelligence (AI) makes the build-versus-buy question particularly important. AI markets are evolving quickly, and firms must...